Korean J Health Promot.  2021 Dec;21(4):129-133. 10.15384/kjhp.2021.21.4.129.

Will Hypomagnesemia Induce Benign Eyelid Myokymia?

• Kim J
• Hyung SW
• Han SK
• Lee JY
• Yu HJ
• Sunwoo MK

• KMID: 2524723
• DOI: http://doi.org/10.15384/kjhp.2021.21.4.129

Abstract

Background
Myokymia consists of involuntary, fine, continuous contraction that spread across the affected striated muscle. Eyelid myokymia, unlike other dystonic facial contracture such as blepharospasm and hemifacial spasm, is assumed to be a benign, self-limited disorder. Eyelid myokymia is associated with stress, fatigue, excercise, and exccessive caffeine use. The pathophysiology is not well understood, but some drugs or brain structural lesions are the cause of the eyelid myokymia. Especially in Korea hypomagnesemia is generally known the main cause of eyelid myokymia, however there are no evidences so far. This study investigated the relation between eyelid myokymia and serum magnesium level.
Methods
We performed a cross sectional study on 72 patients with myokymia and 197 controls. We investigated fatigue, sleep quality, alcohol, smoking, caffeine use, and exercise datas by interview. We analyzed laboratory datas including magnesium, calcium, phosphate, thyroid hormone in serum.
Results
Demographic characteristics between the patients with myokymia and controls showed no significant differences in age, gender, smoking, and alcohol history. Fatigue and poor sleep quality were significantly higher in the myokymia group than control group. However, any laboratory results including magnesium showed no significant differences between two groups.
Conclusions
These data suggested that the eyelid myokymia is not related to the serum magnesium level as well as calcium and phosphate. Only fatigue and sleep quality were shown the relationship with eyelid myokymia.

Keyword

Myokymia; Fasciculation; Magnesium; Hypomagnesemia; Fatigue

Reference

1. Boghen DR. Disorders of facial motor function. Curr Opin Ophthalmol. 1996; 7(6):48–52.

2. Holds JB, White GL Jr, Thiese SM, Anderson RL. Facial dystonia, essential blepharospasm and hemifacial spasm. Am Fam Physician. 1991; 43(6):2113–20.

3. Jinnah HA. Medical and surgical treatments for dystonia. Neurol Clin. 2020; 38(2):325–48.

4. Jafer Chardoub AA, Patel BC. Eyelid myokymia. Treasure Island: StatPearls Publishing LLC;2021. p. 1–8.

5. Givner I, Jaffe NS. Myokymia of the eyelids; a suggestion as to therapy; preliminary report. Am J Ophthalmol. 1949; 32(1):51–5.

6. Howell NA, Maher J, Fasano A. Acetazolamide-induced myokymia. Parkinsonism Relat Disord. 2015; 21(5):542–3.

7. Khalkhali M. Topiramate-induced persistent eyelid myokymia. Case Rep Psychiatry. 2016; 2016:7901085.

8. Hertz R, Espinosa J, Lucerna A, Stranges D. Multiple sclerosis presenting with facial twitching (myokymia and hemifacial spasms). Case Rep Neurol Med. 2017; 2017:7180560.

9. Kitaguchi Y, Sabundayo MS, Kakizaki H. Eyelid myokymia with concomitant cerebral tumour: a case report. Neuroophthalmology. 2017; 42(3):150–2.

10. Yu SB, Lew H, Yun YS. Therapeutic effect of botulinium toxin injection in eyelid myokymia patients. J Korean Ophthalmol Soc. 2007; 48(6):749–54.

11. Banik R, Miller NR. Chronic myokymia limited to the eyelid is a benign condition. J Neuroophthalmol. 2004; 24(4):290–2.

12. Hadžić S, Kukić I, Zvorničanin J. The prevalence of eyelid myokymia in medical students. Br J Med Res. 2016; 14(6):1–6.

13. Vink R, Nechifor M. Magnesium in the central nervous system. Adelaide: University of Adelaide Press;2011. p. 3–12.

14. Kirkland AE, Sarlo GL, Holton KF. The role of magnesium in neurological disorders. Nutrients. 2018; 10(6):730.

15. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008; 7(8):742–55.

16. Mert T, Gunes Y, Guven M, Gunay I, Ozcengiz D. Effects of calcium and magnesium on peripheral nerve conduction. Pol J Pharmacol. 2003; 55(1):25–30.

17. Sawlani K, Katirji B. Peripheral nerve hyperexcitability syndromes. Continuum (Minneap Minn). 2017; 23((5, Peripheral Nerve and Motor Neuron Disorders)):1437–50.

18. de Carvalho M, Kiernan MC, Swash M. Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance. J Neurol Neurosurg Psychiatry. 2017; 88(9):773–9.

19. Pham PC, Pham PA, Pham SV, Pham PT, Pham PM, Pham PT. Hypomagnesemia: a clinical perspective. Int J Nephrol Renovasc Dis. 2014; 7:219–30.

20. Barna O, Lohoida P, Holovchenko Y, Bazylevych A, Velychko V, Hovbakh I, et al. A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps. Nutr J. 2021; 20(1):90.

21. Garrison SR, Allan GM, Sekhon RK, Musini VM, Khan KM. Magnesium for skeletal muscle cramps. Cochrane Database Syst Revs. 2012; (9):CD009402.